EBS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EBS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Emergent BioSolutions's change in receivables for the quarter that ended in Dec. 2023 was $37 Mil. It means Emergent BioSolutions's Accounts Receivable declined by $37 Mil from Sep. 2023 to Dec. 2023 .
Emergent BioSolutions's change in receivables for the fiscal year that ended in Dec. 2023 was $-22 Mil. It means Emergent BioSolutions's Accounts Receivable increased by $22 Mil from Dec. 2022 to Dec. 2023 .
Emergent BioSolutions's Accounts Receivable for the quarter that ended in Dec. 2023 was $142 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Emergent BioSolutions's Days Sales Outstanding for the three months ended in Dec. 2023 was 47.94.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Emergent BioSolutions's liquidation value for the three months ended in Dec. 2023 was $-791 Mil.
The historical data trend for Emergent BioSolutions's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | -8.20 | 27.50 | -16.20 | 118.10 | -21.60 |
Emergent BioSolutions Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Change In Receivables | Get a 7-Day Free Trial | 35.60 | 1.80 | -132.40 | 72.10 | 36.90 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions (NYSE:EBS) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Emergent BioSolutions's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 141.8 | / | 269.9 | * | 91 |
= | 47.94 |
2. In Ben Graham's calculation of liquidation value, Emergent BioSolutions's accounts receivable are only considered to be worth 75% of book value:
Emergent BioSolutions's liquidation value for the quarter that ended in Dec. 2023 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 111.7 | - | 1173.9 | + | 0.75 * 141.8 | + | 0.5 * 328.9 |
= | -791 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Emergent BioSolutions's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Neal Franklin Fowler | director | C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879 |
Donald W Degolyer | director | 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879 |
William Hartzel | officer: SVP, Bioservices | 400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879 |
Miller H Haywood Iii | officer: Interim CEO | EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879 |
Kathryn C Zoon | director | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
Paul Anthony Williams | officer: SVP, Products Business | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
Ronald Richard | director | 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850 |
Sujata Tyagi Dayal | director | C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587 |
Keith Katkin | director | C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617 |
Glessner Coleen | officer: EVP, Quality & Ethics, and CPL | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
Jennifer Lynne Fox | officer: EVP, Ext Aff, GC, Corp Sec | 400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879 |
Richard S Lindahl | officer: EVP, Chief Financial Officer | NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191 |
Sue Bailey | director | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850 |
Adam Havey | officer: EVP, BioDefense Division | 2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853 |
Robert Kramer | officer: Interim, EVP, BioSciences | 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850 |
From GuruFocus
By Value_Insider Value_Insider • 10-18-2022
By Value_Insider Value_Insider • 12-06-2022
By Marketwired • 10-02-2023
By Marketwired • 07-20-2023
By sperokesalga sperokesalga • 02-15-2023
By sperokesalga sperokesalga • 05-11-2023
By Marketwired • 07-31-2023
By sperokesalga sperokesalga • 03-29-2023
By Value_Insider Value_Insider • 11-14-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.